|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||84.30 - 84.95|
|52 Week Range||69.53 - 86.90|
|PE Ratio (TTM)||30.23|
|Forward Dividend & Yield||2.72 (3.21%)|
|1y Target Est||N/A|
Several presentations at the annual meeting of the American Society of Hematology grab headlines in the cancer space.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Novartis AG Here are 5 ETFs with the largest exposure to NVS-US. Comparing the performance and risk of Novartis AG with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
The FDA could further pressure generic drugmakers in 2018 by continuing along its path of increased generic approvals.
The curtains have come down on one of the most-watched annual biotech conferences. The 59th annual meeting of the American Society of Hematology was held Dec. 9-12 in Atlanta. This year's meeting was ...
Swiss drugmaker Novartis's Sandoz generics business is in the process of selling or closing some products in the United States, it said on Wednesday. "In response to high price pressure, we are optimizing our U.S. portfolio. "As we continue to refine our portfolio, it is clear that the U.S. market is a very important market for Sandoz and will continue to be in the future," it added.
Novartis (NVS) announced positive data from a phase II study, SUSTAIN, on pipeline candidate crizanlizumab which deferred the time to first sickle cell pain crisis (SCPC) in patients compared to placebo in key subgroups of adult patients with sickle cell.
Novartis (NVS) announced updated results from the JULIET study, which show Kymriah sustained complete responses at six months in adults with relapsed or refractory diffuse large B-cell lymphoma.
Shares of Bluebird Bio (BLUE) were up nearly 20% in early morning trading Monday as investors responded to the company's announcement that its CAR-T candidate, bb2121, produced encouraging results in patients with a deadly blood cancer.
Shares of Gilead Sciences (GILD) are higher on Monday, building on its strength from Friday when it announced its acquisition of Cell Design Labs. Gilead got a boost today from its its presentation at the American Society of Hematology's (ASH) annual meeting, where it and other companies provided update on their CAR-T therapies aimed at cancer. BMO Capital Markets' M. Ian Somaiya wrote that the news was good for Gilead and its peers: Updates from the three leading trials of CD-19 CAR-T therapy in DLBCL (GILD's Yescarta, Juno Therapeutics' (JUNO) JCAR017, Novartis' (NVS) Kymriah) raise the bar yet again for CAR-Ts.
Switzerland’s stocks are changing hands below their typical premium, the Swiss franc appears poised to slide further against the euro, and earnings growth looks good.
Patients with an advanced form of an aggressive blood cancer who had initially responded to Novartis' new type of gene-modifying immunotherapy continued to respond at least six months after treatment, according to updated data released at a medical meeting on Sunday. Among 46 patients with at least six months of follow-up after treatment with Novartis' Kymriah for diffuse large B-cell lymphoma (DLBCL), 30 percent still had a complete response, meaning no detectable sign of cancer, with another 7 percent achieving a partial response.
Prosecutors in Rome have been looking into charges the two companies colluded to discredit eye disease drug Avastin by emphasizing its potential side effects in order to boost sales of Lucentis, a more expensive alternative which offers similar treatment. Both Avastin and Lucentis are manufactured by Roche but Lucentis is marketed by Novartis outside the United States.
Pfizer (PFE) releases impressive new data of a post-hoc analysis from a phase III study on the combo therapy of Ibrance and Femara for the first-line treatment of ER+, HER2- metastatic breast cancer.
So far in this trial, ribociclib extended PFS by around a year (23.8 vs. 13.0 months). That’s a dramatic and early result.
Wall Street analysts estimate that GlaxoSmithKline’s (GSK) top line could fall 0.8% to ~7.5 billion pounds in 4Q17.
The ACCC alleged that the companies tried to market their two pain relief products, Osteo Gel and Emulgel, as having different levels of impact in treating osteoarthritis, when in fact they are "identically formulated". "We allege that consumers are likely to have been misled into purchasing Osteo Gel thinking that it is different to Emulgel and more effective for treating osteoarthritis conditions, when this is not the case”, ACCC Chairman Rod Sims said.
Of the four analysts tracking Novartis ADR, two recommend a “buy,” while two recommend a “hold.” None recommends a “sell.”
Novartis reported a 2% YoY rise in revenues at constant exchange rates to ~$12.4 billion in 3Q17. Here, we'll look at the company's key developments.
In 3Q17, GlaxoSmithKline (GSK) surpassed Wall Street analysts’ estimates for its earnings per share. GSK reported revenues of ~7.8 billion pounds, missing the estimate of 7.9 billion pounds.
Shares of generic drug manufacturers are rising on a report stating that Amazon.com held talks with Mylan and Novartis’ Sandoz about entering the pharmacy business, while shares of distributors and drugstores ...
This segment contributed ~66.9% of Novartis's total revenues in 3Q17, reporting ~$8.3 billion, which represents 2% YoY (year-over-year).